Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission.
Jaume MoraAlicia CastañedaMaite GorosteguiVicente Santa-MaríaMoira GarrausJuan Pablo MuñozAmalia VaroSara Perez-JaumeSalvador MañePublished in: Pediatric blood & cancer (2021)
Consolidation with naxitamab and GM-CSF resulted in excellent survival rates for HR-NB patients in CR.